Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

106.47 +2.80 (+2.70%)
Streaming Delayed Price Updated: 3:37 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
The Top Healthcare Stocks to Buy With $100
You don't need a fortune to start investing. 
Via The Motley Fool
Prediction: These 2 Stocks Could Double In the Next Year
It would be a continuation of solid recent performances. 
Via The Motley Fool
2 Biotech Stocks That Could Help Set You Up for Life
These two promising companies have the potential to beat the market over time. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Axsome Therapeutics's Return On Capital Employed Overview
Via Benzinga
2 Bear Market Defying Stocks to Buy in May
These stocks still have plenty of market-beating years ahead. 
Via The Motley Fool
3 Growth Stocks to Buy and Hold
These three stocks defied the bear market last year. 
Via The Motley Fool
Expert Ratings for Axsome Therapeutics
Via Benzinga
Earnings Outlook For Axsome Therapeutics
Via Benzinga
Axsome Therapeutics Stock: Bear vs. Bull
Axsome shares beat the bear market last year. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both Axsome Therapeutics and Exelixis have potentially game-changing products in their pipelines. 
Via The Motley Fool
Is a Victory for Its Rivals Bad News for Axsome Therapeutics?
The biopharmaceutical company's shares have soared during the past year. 
Via The Motley Fool
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review
The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones. 
Via Investor's Business Daily
This Analyst Creates Bullish Pitch For Axsome Therapeutics On Increased Outlook For Its Depression Drug
Mizuho increased the price target on Axsome Therapeutics Inc (NASDAQ: AXSM) from $84 to $95 with a Buy rating 
Via Benzinga
2 Beaten-Down Growth Stocks to Buy in April
These companies have lucrative opportunities ahead. 
Via The Motley Fool
Could Axsome Therapeutics Stock Help You Become a Millionaire?
In the past five years, the stock has risen by nearly 2,400%. 
Via The Motley Fool
Is It Too Late to Buy Axsome Therapeutics Stock?
With two major catalysts in the rearview mirror, it's easy to think that it's too late. 
Via The Motley Fool
2 Magnificent Growth Stocks You Can Buy With $150 Right Now
You don't have to wait until you're rich to start getting your money to work for you. 
Via The Motley Fool
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
The biotech's share price more than doubled during last year's bear market. 
Via The Motley Fool
Axsome Therapeutics Clocks Better Than Expected Q1 Sales, Depression Drug Sees Improved Coverage
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q1 revenue of $94.6 million, consisting of net product sales of $28.6 million, license revenue of $65.7 million, and  
Via Benzinga
Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript
AXSM earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Axsome Surges As Its Newest Product Shines. But BioXcel Does The Opposite.
Axsome shares are nearing a breakout point. But BioXcel crumbled on its report. 
Via Investor's Business Daily
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023 
Via InvestorPlace
3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat
Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat. 
Via InvestorPlace
If You Invested $5,000 in Axsome Therapeutics 5 Years Ago, Here's How Much You Would Have Now
Axsome's new products have blockbuster potential. 
Via The Motley Fool
3 Stocks With Huge Catalysts on the Way
Big news could mean big boosts for these stocks. 
Via The Motley Fool
The Top 3 Biotech Stocks to Watch in 2023
Investors would be wise to keep an eye on the biotech boom, and these top biotech stocks to watch as we get deeper into 2023. 
Via InvestorPlace
1 Risky Growth Stock Wall Street Says Is Poised for a 47% Rally
Its price should keep rising, but perhaps Wall Street is a bit enthusiastic with its forecasts. 
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
A small investment now may bring big results over time. 
Via The Motley Fool
Better Growth Stock: Axsome vs. CRISPR Therapeutics
These companies are both in the early days of their growth stories. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.